National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Pembrolizumab (Keytruda ®) is indicated as monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 06/12/2017
Rapid review completed 21/12/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended